We focused specifically on these pathways as SNX2112 antitumor activity has been shown to be mediated by PI3K/AKT and MEK/ERK1/2 pathways in other cancers including MET-amplified gastric and lung cancers, HER kinase dependent cancers, multiple myeloma and other hematologic tumors [19, 25, 26]; however, it is entirely possible that other HSP90 clients play additional roles in mediating the anti-tumor effects we observed. Here, MET is linked to plasma cell myeloma.